Trial Outcomes & Findings for Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly (NCT NCT04985877)
NCT ID: NCT04985877
Last Updated: 2026-02-17
Results Overview
The V1-V9 region of the 16S rRNA gene was amplified by PCR following the Illumina 16S Metagenomic Sequencing Library Preparation protocol and sequenced on an Illumina MiSeq 2000 platform. Data analysis used QIIME2 with UPARSE for OTU clustering (97% similarity), Shannon index for alpha diversity, weighted PCoA for beta diversity, and LEfSe via Galaxy for differential analysis. In sarcopenia patients, Synergistaceae and Oscillibacter are elevated while Bifidobacterium is reduced. Post-intervention improvement (decreased Synergistaceae/Oscillibacter, increased Bifidobacterium) alleviates dysbiosis, lowers inflammation, and enhances gut-muscle axis function. This shift boosts SCFA production, muscle protein synthesis, grip strength, and mass while reducing pathogen-induced insulin resistance for metabolic recovery and symptom relief.
COMPLETED
NA
132 participants
12 week
2026-02-17
Participant Flow
Subjects are recruited from Taipei Medical University Hospital, Shuang Ho Hospital, Taipei Municipal Wanfang Hospital, and Taipei Community Care (Stone Soup). Participants who fail the first screening are classified as NS group. Those who pass second screening will be randomized into SC or LcS group.
First screening: (1)Calf Circumference(cm): Men\<34, Women\<33;(2)SARC-F Score≥4. Second screening: (3)SMI: Men\<7.0, Women\<5.7;(4)Handgrip Strength(kg): Men\<28, Women\<18;(5)Limb Strength Test≥12 sec. Sarcopenia is defined as meeting (3) and at least one of (4) or (5). If any participants withdraw during the trial, recruitment will continue until each group reaches a total of 40 completed cases.
Participant milestones
| Measure |
NS Group
Subjects meet the inclusion and exclusion criterias and are not a sarcopenia patients based on the algorithm of Asian Working Group for Sarcopenia (AWGS).
|
SC Group
Subjects meet the inclusion and exclusion criterias and be divided into groups according to the definition of sarcopenia is based on the algorithm of Asian Working Group for Sarcopenia (AWGS).
|
LcS Group
Subjects meet the inclusion and exclusion criterias and be divided into groups according to the definition of sarcopenia is based on the algorithm of Asian Working Group for Sarcopenia (AWGS). LcS group has intervention between pre-test and post-test.
|
|---|---|---|---|
|
Overall Study
STARTED
|
40
|
46
|
46
|
|
Overall Study
COMPLETED
|
40
|
40
|
40
|
|
Overall Study
NOT COMPLETED
|
0
|
6
|
6
|
Reasons for withdrawal
| Measure |
NS Group
Subjects meet the inclusion and exclusion criterias and are not a sarcopenia patients based on the algorithm of Asian Working Group for Sarcopenia (AWGS).
|
SC Group
Subjects meet the inclusion and exclusion criterias and be divided into groups according to the definition of sarcopenia is based on the algorithm of Asian Working Group for Sarcopenia (AWGS).
|
LcS Group
Subjects meet the inclusion and exclusion criterias and be divided into groups according to the definition of sarcopenia is based on the algorithm of Asian Working Group for Sarcopenia (AWGS). LcS group has intervention between pre-test and post-test.
|
|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
0
|
6
|
6
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
NS Group
n=40 Participants
Inclusion Criteria
1\. Age between 65 and 85 years 2. No use of hormonal replacement therapy (women) 3. No hospital admissions within the last 3 months 4. No Sarcopenia criteria:
1. Normal muscle mass was defined as:
1. Men: SMI ≧7.0 kg/m2
2. Women: SMI ≧5.7 kg/m2
2. Normal handgrip strength was defined as:
1. Men: ≧28 kg
2. Women: ≧18 kg
3. Normal limb strength was defined as:
1. Time for 5 times for chair stand: \<12s
Exclusion Criteria
1. Active cancer: currently receiving cancer treatment or have received cancer treatment within the last 3 months
2. Weight change ≥ 5% or weight change ≥ 5 kg within the past 3 months
3. BMI \> 35 kg/m2
4. Disease requiring chronic use of prescription corticosteroids
5. History of ischemic or hemorrhage stroke
6. Unstable or uncontrollable hypertension (\>180/110 mmHg)
7. Doing hemodialysis or peritoneal dialysis within the last 3 months
8. Participation in a structured physical exercise training program within the past 2 year; previous use of creatinine supplementation; use of drugs that can affect bone metabolism (e.g., glucocorticoids, bisphosphonates, vitamin D or calcium).
9. Antibiotics were used in the past 3 months.
10. Products of probiotic were used in the past 2 weeks.
11. Living abroad for one month in the past 3 months
12. Hyperthyroidism without medication therapy
13. Allergic to milk
|
SC Group
n=46 Participants
Inclusion Criteria
1\. Age between 65 and 85 years 2. No use of hormonal replacement therapy (women) 3. No hospital admissions within the last 3 months 4. No Sarcopenia criteria:
1. Low muscle mass was defined as:
1. Men: SMI \<7.0 kg/m2
2. Women: SMI \<5.7 kg/m2
2. Low handgrip strength was defined as:
1. Men: \<28 kg
2. Women: \<18 kg
3. Low limb strength was defined as:
1. Time for 5 times for chair stand: ≧12s
Exclusion Criteria
1. Active cancer: currently receiving cancer treatment or have received cancer treatment within the last 3 months
2. Weight change ≥ 5% or weight change ≥ 5 kg within the past 3 months
3. BMI \> 35 kg/m2
4. Disease requiring chronic use of prescription corticosteroids
5. History of ischemic or hemorrhage stroke
6. Unstable or uncontrollable hypertension (\>180/110 mmHg)
7. Doing hemodialysis or peritoneal dialysis within the last 3 months
8. Participation in a structured physical exercise training program within the past 2 year; previous use of creatinine supplementation; use of drugs that can affect bone metabolism (e.g., glucocorticoids, bisphosphonates, vitamin D or calcium).
9. Antibiotics were used in the past 3 months.
10. Products of probiotic were used in the past 2 weeks.
11. Living abroad for one month in the past 3 months
12. Hyperthyroidism without medication therapy
13. Allergic to milk
|
LcS Group
n=46 Participants
Inclusion Criteria
1\. Age between 65 and 85 years 2. No use of hormonal replacement therapy (women) 3. No hospital admissions within the last 3 months 4. No Sarcopenia criteria:
1. Low muscle mass was defined as:
1. Men: SMI \<7.0 kg/m2
2. Women: SMI \<5.7 kg/m2
2. Low handgrip strength was defined as:
1. Men: \<28 kg
2. Women: \<18 kg
3. Low limb strength was defined as:
1. Time for 5 times for chair stand: ≧12s
Exclusion Criteria
1. Active cancer: currently receiving cancer treatment or have received cancer treatment within the last 3 months
2. Weight change ≥ 5% or weight change ≥ 5 kg within the past 3 months
3. BMI \> 35 kg/m2
4. Disease requiring chronic use of prescription corticosteroids
5. History of ischemic or hemorrhage stroke
6. Unstable or uncontrollable hypertension (\>180/110 mmHg)
7. Doing hemodialysis or peritoneal dialysis within the last 3 months
8. Participation in a structured physical exercise training program within the past 2 year; previous use of creatinine supplementation; use of drugs that can affect bone metabolism (e.g., glucocorticoids, bisphosphonates, vitamin D or calcium).
9. Antibiotics were used in the past 3 months.
10. Products of probiotic were used in the past 2 weeks.
11. Living abroad for one month in the past 3 months
12. Hyperthyroidism without medication therapy
13. Allergic to milk
|
Total
n=132 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=40 Participants
|
0 Participants
n=46 Participants
|
0 Participants
n=46 Participants
|
0 Participants
n=132 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=40 Participants
|
0 Participants
n=46 Participants
|
0 Participants
n=46 Participants
|
0 Participants
n=132 Participants
|
|
Age, Categorical
>=65 years
|
40 Participants
n=40 Participants
|
46 Participants
n=46 Participants
|
46 Participants
n=46 Participants
|
132 Participants
n=132 Participants
|
|
Age, Continuous
|
73 years old
n=40 Participants
|
74 years old
n=46 Participants
|
72.5 years old
n=46 Participants
|
73 years old
n=132 Participants
|
|
Sex: Female, Male
Female
|
28 Participants
n=40 Participants
|
32 Participants
n=46 Participants
|
38 Participants
n=46 Participants
|
98 Participants
n=132 Participants
|
|
Sex: Female, Male
Male
|
12 Participants
n=40 Participants
|
14 Participants
n=46 Participants
|
8 Participants
n=46 Participants
|
34 Participants
n=132 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
Taiwan
|
40 participants
n=40 Participants
|
46 participants
n=46 Participants
|
46 participants
n=46 Participants
|
132 participants
n=132 Participants
|
PRIMARY outcome
Timeframe: 12 weekPopulation: The sample of one subject from LcS group is not enough to do this test, so overall number of participants analyzed for LcS group is 39.
The V1-V9 region of the 16S rRNA gene was amplified by PCR following the Illumina 16S Metagenomic Sequencing Library Preparation protocol and sequenced on an Illumina MiSeq 2000 platform. Data analysis used QIIME2 with UPARSE for OTU clustering (97% similarity), Shannon index for alpha diversity, weighted PCoA for beta diversity, and LEfSe via Galaxy for differential analysis. In sarcopenia patients, Synergistaceae and Oscillibacter are elevated while Bifidobacterium is reduced. Post-intervention improvement (decreased Synergistaceae/Oscillibacter, increased Bifidobacterium) alleviates dysbiosis, lowers inflammation, and enhances gut-muscle axis function. This shift boosts SCFA production, muscle protein synthesis, grip strength, and mass while reducing pathogen-induced insulin resistance for metabolic recovery and symptom relief.
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=39 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Gut Microbiota
Synergistaceae
|
0.023577513 % of total Bacteria
Standard Deviation 0.117944329
|
0.248239465 % of total Bacteria
Standard Deviation 1.098091371
|
0.003810442 % of total Bacteria
Standard Deviation 0.016458261
|
|
Impact of LCS on the Change of Gut Microbiota
Oscillibacter
|
0.10325558 % of total Bacteria
Standard Deviation 0.195762068
|
0.374706279 % of total Bacteria
Standard Deviation 0.547100278
|
0.173954697 % of total Bacteria
Standard Deviation 0.3926609
|
|
Impact of LCS on the Change of Gut Microbiota
Bifidobacterium
|
4.769980895 % of total Bacteria
Standard Deviation 8.312128461
|
1.556790926 % of total Bacteria
Standard Deviation 2.600366407
|
4.660690126 % of total Bacteria
Standard Deviation 7.195860445
|
SECONDARY outcome
Timeframe: 12 weekHandgrip: The measurement used electronic hand grip dynamometer. Low handgrip strength was defined as Men: \<28 kg; Women: \<18kg.
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Sarcopenia Markers (Handgrip)
|
22.17 kg
Interval 17.0 to 25.88
|
18.95 kg
Interval 15.73 to 21.54
|
19.07 kg
Interval 16.13 to 22.25
|
SECONDARY outcome
Timeframe: 12 weeksWalk speed: The time required for participants to walk 6 meters along the line.
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Sarcopenia Markers (Walk Speed)
|
0.89 m/sec
Interval 0.73 to 1.03
|
0.82 m/sec
Interval 0.69 to 0.91
|
1.08 m/sec
Interval 0.76 to 1.14
|
SECONDARY outcome
Timeframe: 12 weekChair stand test (second): Participants sat and stood five times, and time was calculated using a timer. Low limb strength was defined time ≧12s. TUG:Participants were instructed to stand up from the chair, walk 3 meters forward and go back to sit on the chair. Low Physical performance was defined ≧ 20s.
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Sarcopenia Markers (Chair Stand Test & TUG Test)
Chair stand test (second)
|
12.91 sec
Interval 10.39 to 15.62
|
14.95 sec
Interval 12.01 to 18.36
|
12.31 sec
Interval 8.8 to 14.73
|
|
Impact of LCS on the Change of Sarcopenia Markers (Chair Stand Test & TUG Test)
TUG test
|
10.12 sec
Interval 8.78 to 12.61
|
11.18 sec
Interval 8.71 to 13.38
|
9.06 sec
Interval 7.82 to 12.68
|
SECONDARY outcome
Timeframe: 12 weeksThe Short Physical Performance Battery (SPPB) is a validated objective assessment tool developed by the National Institute on Aging to evaluate lower extremity function in older adults. It comprises three standardized components administered in sequence: a balance test (side-by-side, semi-tandem, and tandem stands), a 4-meter gait speed test, and a five-times chair stand test, each scored from 0-4 based on time or ability, yielding a total score of 0-12. Higher scores (10-12: minimal limitations; 4-6: moderate; 0-3: severe) indicate better physical performance and predict lower risks of mobility disability, falls, hospitalization, and mortality. The SPPB takes \~10 minutes, requires minimal equipment, and demonstrates excellent reliability for clinical and research use in geriatric populations, including sarcopenia studies. Low Physical performance was defined ≦ 9 scores
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Sarcopenia Markers (SPPB Score)
|
11 point
Interval 8.75 to 12.0
|
9 point
Interval 8.0 to 11.0
|
11 point
Interval 9.0 to 12.0
|
SECONDARY outcome
Timeframe: 12 weekSerum pro-inflammatory cytokines (IL-6 and TNF-α) and anti-inflammatory cytokines (IL-10, IL-17 and TGF-β) were determined by using ELISA Kits (Elabscience Biotechnology Inc) via ELISA reader (BioTek, PowerWave XS2, City, State, USA).
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Inflammatory Biomarker
TNF-alpha
|
5.97 pg/mL
Interval 4.42 to 11.96
|
29.30 pg/mL
Interval 9.35 to 76.46
|
7.94 pg/mL
Interval 3.57 to 38.8
|
|
Impact of LCS on the Change of Inflammatory Biomarker
TGF-beta
|
22520 pg/mL
Interval 17903.0 to 26783.0
|
5050 pg/mL
Interval 3229.0 to 13335.0
|
16600 pg/mL
Interval 3607.0 to 20598.0
|
|
Impact of LCS on the Change of Inflammatory Biomarker
IL-17
|
32.25 pg/mL
Interval 9.38 to 104.52
|
8.32 pg/mL
Interval 5.3 to 17.81
|
9.38 pg/mL
Interval 8.75 to 31.48
|
|
Impact of LCS on the Change of Inflammatory Biomarker
IL-10
|
3.45 pg/mL
Interval 1.7 to 5.26
|
0.5 pg/mL
Interval 0.5 to 3.18
|
0.52 pg/mL
Interval 0.5 to 5.1
|
|
Impact of LCS on the Change of Inflammatory Biomarker
IL-6
|
0.47 pg/mL
Interval 0.47 to 1.51
|
7.06 pg/mL
Interval 1.27 to 17.5
|
7.70 pg/mL
Interval 1.29 to 14.39
|
SECONDARY outcome
Timeframe: 12 weekSuperoxide dismutase (SOD) (E-BC-K019, Elabscience Biotechnology Inc.), Glutathione peroxidase (GPx) (E-BC-K096, Elabscience Inc.) and Catalase (CAT) (E-BC-K031, Elabscience Biotechnology Inc.) are antioxidant enzymes in human. Enzymatic activity in serum was determined by using ELISA Kits via ELISA reader (BioTek, PowerWave XS2, City, State, USA).
Outcome measures
| Measure |
NS Group
n=40 Participants
non-sarcopenia patients
|
SC Group
n=40 Participants
Sarcopenia patients
|
LcS Group
n=40 Participants
Sarcopenia patients have intervention with Shirota for 12 weeks.
|
|---|---|---|---|
|
Impact of LCS on the Change of Anti-oxidant Biomarker
CAT activity
|
39 U/mL
Interval 29.0 to 47.0
|
38 U/mL
Interval 23.0 to 50.0
|
26 U/mL
Interval 14.0 to 40.0
|
|
Impact of LCS on the Change of Anti-oxidant Biomarker
GPx activity
|
111 U/mL
Interval 101.0 to 119.0
|
106 U/mL
Interval 97.0 to 113.0
|
105 U/mL
Interval 95.0 to 116.0
|
|
Impact of LCS on the Change of Anti-oxidant Biomarker
SOD activity
|
191 U/mL
Interval 184.0 to 196.0
|
200 U/mL
Interval 137.0 to 234.0
|
159 U/mL
Interval 123.0 to 239.0
|
Adverse Events
NS Group
SC Group
LcS Group
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place